Literature DB >> 31100442

Cis-regulatory genetic variants in the CCR5 gene and natural HIV-1 control in black South Africans.

Gemma W Koor1, Maria Paximadis2, Anabela C P Picton1, Fidan Karatas1, Shayne A Loubser1, Weijing He3, Sunil K Ahuja4, Richard E Chaisson5, Neil Martinson6, Osman Ebrahim7, Caroline T Tiemessen1.   

Abstract

Studies have investigated CCR5 haplotypes (HHA, HHB, HHC, HHD, HHE, HHF*1, HHF*2, HHG*1, HHG*2), defined by seven 5'UTR single nucleotide polymorphisms (SNPs), CCR2-V64I and CCR5Δ32, in HIV-1 disease. CCR5 cis-regulatory regions were sequenced, CCR2-V64I and CCR5Δ32 genotyped, and compared in HIV-1-infected black South Africans: 71 HIV-1 controllers (23 elite controllers, 37 viraemic controllers (VCs), 11 high viral load long-term non-progressors) and 74 progressors. The HHE haplotype and 3'UTR +2919 T > G SNP heterozygosity were underrepresented in total controllers and VCs vs. progressors (p = .004; p = .007 and p = .002, pbonferroni = 0.032; p = .004, respectively). Possession of the +2919 T > G SNP (dominant mode) was associated with HIV-1 progression (controllers vs. progressors: p = .001, pbonferroni = 0.016). The +2919 T > G SNP is in linkage disequilibrium (LD; r2 = 0.73) with two 5'UTR SNPs (-2459G > A and -2135 T > C; r2 = 1: 5'UTR-2SNP-hap). The 5'UTR-2SNP-hap was lower in total controllers and VCs vs. progressors (p = .003, pbonferroni = 0.048; p = .01, respectively). Results suggest -2459G > A, -2135 T > C, and + 2919 T > G as key CCR5 variants in HIV-1 control.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CCR5; Cis-regulatory regions; Genetic variants; HIV-1; Natural control; South Africa

Year:  2019        PMID: 31100442      PMCID: PMC6646080          DOI: 10.1016/j.clim.2019.05.009

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  30 in total

1.  Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes.

Authors:  E Gonzalez; M Bamshad; N Sato; S Mummidi; R Dhanda; G Catano; S Cabrera; M McBride; X H Cao; G Merrill; P O'Connell; D W Bowden; B I Freedman; S A Anderson; E A Walter; J S Evans; K T Stephan; R A Clark; S Tyagi; S S Ahuja; M J Dolan; S K Ahuja
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

2.  Haploview: analysis and visualization of LD and haplotype maps.

Authors:  J C Barrett; B Fry; J Maller; M J Daly
Journal:  Bioinformatics       Date:  2004-08-05       Impact factor: 6.937

3.  CCR5 promoter polymorphisms, CCR5 59029A and CCR5 59353C, are under represented in HIV-1-infected long-term non-progressors. The Australian Long-Term Non-Progressor Study Group.

Authors:  A O Clegg; L J Ashton; R A Biti; P Badhwar; P Williamson; J M Kaldor; G J Stewart
Journal:  AIDS       Date:  2000-01-28       Impact factor: 4.177

4.  CCR5 promoter polymorphism determines macrophage CCR5 density and magnitude of HIV-1 propagation in vitro.

Authors:  Janelle R Salkowitz; Shannon E Bruse; Howard Meyerson; Hernan Valdez; Donald E Mosier; Clifford V Harding; Peter A Zimmerman; Michael M Lederman
Journal:  Clin Immunol       Date:  2003-09       Impact factor: 3.969

5.  Distribution of chemokine receptor CCR2 and CCR5 genotypes and their relative contribution to human immunodeficiency virus type 1 (HIV-1) seroconversion, early HIV-1 RNA concentration in plasma, and later disease progression.

Authors:  Jianming Tang; Brent Shelton; Nina J Makhatadze; Yuting Zhang; Margaret Schaen; Leslie G Louie; James J Goedert; Eric C Seaberg; Joseph B Margolick; John Mellors; Richard A Kaslow
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 6.  Macrophage inflammatory protein-1.

Authors:  Patricia Menten; Anja Wuyts; Jo Van Damme
Journal:  Cytokine Growth Factor Rev       Date:  2002-12       Impact factor: 7.638

7.  Evolution of human and non-human primate CC chemokine receptor 5 gene and mRNA. Potential roles for haplotype and mRNA diversity, differential haplotype-specific transcriptional activity, and altered transcription factor binding to polymorphic nucleotides in the pathogenesis of HIV-1 and simian immunodeficiency virus.

Authors:  S Mummidi; M Bamshad; S S Ahuja; E Gonzalez; P M Feuillet; K Begum; M C Galvis; V Kostecki; A J Valente; K K Murthy; L Haro; M J Dolan; J S Allan; S K Ahuja
Journal:  J Biol Chem       Date:  2000-06-23       Impact factor: 5.157

8.  Combined effect of CCR5-Delta32 heterozygosity and the CCR5 promoter polymorphism -2459 A/G on CCR5 expression and resistance to human immunodeficiency virus type 1 transmission.

Authors:  Florian Hladik; Huanliang Liu; Emily Speelmon; Devon Livingston-Rosanoff; Sean Wilson; Polachai Sakchalathorn; Yon Hwangbo; Benjamin Greene; Tuofu Zhu; M Juliana McElrath
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  Adverse effect of the CCR5 promoter -2459A allele on HIV-1 disease progression.

Authors:  T B Knudsen; T B Kristiansen; T L Katzenstein; J Eugen-Olsen
Journal:  J Med Virol       Date:  2001-11       Impact factor: 2.327

10.  Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus.

Authors:  A Mangano; E Gonzalez; R Dhanda; G Catano; M Bamshad; A Bock; R Duggirala; K Williams; S Mummidi; R A Clark; S S Ahuja; M J Dolan; R Bologna; L Sen; S K Ahuja
Journal:  J Infect Dis       Date:  2001-05-02       Impact factor: 5.226

View more
  2 in total

1.  Reduced CCR5 Expression and Immune Quiescence in Black South African HIV-1 Controllers.

Authors:  Anabela C P Picton; Maria Paximadis; Gemma W Koor; Avani Bharuthram; Sharon Shalekoff; Ria Lassauniere; Prudence Ive; Caroline T Tiemessen
Journal:  Front Immunol       Date:  2021-12-20       Impact factor: 7.561

Review 2.  Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy.

Authors:  Hager Mohamed; Theodore Gurrola; Rachel Berman; Mackenzie Collins; Ilker K Sariyer; Michael R Nonnemacher; Brian Wigdahl
Journal:  Front Immunol       Date:  2022-01-20       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.